David Rind, ICER CMO
As investigations mount and controversy swirls, Biogen fights back against ICER — and then faces another unanimous slapdown
There’s been no shortage of words written about Biogen’s new Alzheimer’s drug, Aduhelm, since its controversial approval last month. And on Thursday, the biotech attempted …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
